Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Cue Biopharma, Inc. - Common Stock (NQ:CUE)

0.6800 -0.0800 (-10.53%)
Streaming Delayed Price Updated: 1:30 PM EDT, Apr 4, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Cue Biopharma, Inc. - Common Stock

< Previous 1 2 3 4 5 Next >
Where Cue Biopharma Stands With Analysts
Via Benzinga
Cue Biopharma to Present at the Federation of Clinical Immunology Societies (FOCIS) 2023 Annual Meeting
From Cue Biopharma, Inc.
Via GlobeNewswire
Cue Biopharma to Host Investor Call
From Cue Biopharma, Inc.
Via GlobeNewswire
Cue Biopharma Earnings Perspective: Return On Capital Employed
Via Benzinga
Cue Biopharma's Earnings Outlook
Via Benzinga
Cue Biopharma to Present at the Jefferies 2023 Global Healthcare Conference
From Cue Biopharma, Inc.
Via GlobeNewswire
3 Biotech Stocks Sitting on Huge-Upside Catalysts
The biotech boom is hot. According to Grand View, it could be worth $2.44 trillion. It's why we have an eye on these top biotech stocks. 
Via InvestorPlace
Cue Biopharma Presents Positive Data Update from Ongoing Phase 1 Trials of CUE-101 for Recurrent/Metastatic HPV+ Head and Neck Squamous Cell Carcinoma at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting
From Cue Biopharma, Inc.
Via GlobeNewswire
Cue Biopharma to Present at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting
From Cue Biopharma, Inc.
Via GlobeNewswire
Cue Biopharma Reports First Quarter 2023 Financial Results and Recent Business Highlights
From Cue Biopharma, Inc.
Via GlobeNewswire
Cue Biopharma to Present at the Upcoming JMP Securities Life Sciences Conference
From Cue Biopharma, Inc.
Via GlobeNewswire
7 Hot Growth Stocks Poised to Triple in 2023
These hot growth stocks to buy can triple in price in 2023, with some holding impressive upside that's much higher. 
Via InvestorPlace
7 High-Potential Penny Stocks in the Biotech Sector
Most of the biggest biotech stocks on the market started off as unknown penny stocks. Here are seven hot ones to consider. 
Via InvestorPlace
Cue Biopharma Welcomes Seasoned Pharmaceutical Executive Pamela D. Garzone, Ph.D., to its Board of Directors
From Cue Biopharma, Inc.
Via GlobeNewswire
Cue Biopharma Welcomes Industry Veteran Mr. Patrick Verheyen to its Board of Directors
From Cue Biopharma, Inc.
Via GlobeNewswire
Cue Biopharma Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Business Highlights
From Cue Biopharma, Inc.
Via GlobeNewswire
Earnings Scheduled For March 21, 2023
Companies Reporting Before The Bell • LumiraDx (NASDAQ:LMDX) is projected to report quarterly loss at $0.20 per share on revenue of $41.75 million. 
Via Benzinga
Cue Biopharma to Host Business Update Call and Webcast
From Cue Biopharma, Inc.
Via GlobeNewswire
Cue Biopharma to Present at Two March 2023 Investor Healthcare Conferences
From Cue Biopharma, Inc.
Via GlobeNewswire
Cue Biopharma Enters into a Strategic Collaboration and Option Agreement with Ono Pharmaceutical for CUE-401
From Cue Biopharma, Inc.
Via GlobeNewswire
Cue Biopharma’s Therapeutic Immuno-STAT Biologics to be Featured in Oxford University Presentation at the 67th Biophysical Society Annual Meeting
From Cue Biopharma, Inc.
Via GlobeNewswire
Cue Biopharma Announces the Appointment of Dr. Rafi Ahmed to its Scientific Advisory Board
From Cue Biopharma, Inc.
Via GlobeNewswire
Cue Biopharma to Present at Two February 2023 Scientific Conferences
From Cue Biopharma, Inc.
Via GlobeNewswire
Cue Biopharma Announces Chief Medical Officer Transition
From Cue Biopharma, Inc.
Via GlobeNewswire
Cue Biopharma to Present at Two Upcoming Investor Healthcare Conferences
From Cue Biopharma, Inc.
Via GlobeNewswire
Public Ventures LLC Completes First Public Company Financing as a Broker-Dealer for Cue Biopharma, Inc. (Nasdaq:CUE)
Via ACCESSWIRE
Cue Biopharma Reports Third Quarter 2022 Financial Results
From Cue Biopharma, Inc.
Via GlobeNewswire
Cue Biopharma Announces $30 Million Private Investment in Public Equity (PIPE) Financing
From Cue Biopharma, Inc.
Via GlobeNewswire
Cue Biopharma Presents New Positive Data from Ongoing Phase 1 Trial of CUE-101 in Combination with KEYTRUDA(R) for Recurrent/Metastatic HPV+ Head and Neck Cancer at the Society for Immunotherapy of Cancer’s (SITC) 37th Annual Meeting
From Cue Biopharma, Inc.
Via GlobeNewswire
Cue Biopharma to Present at Two Upcoming Investor Healthcare Conferences in November
From Cue Biopharma, Inc.
Via GlobeNewswire
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.